BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251002T190000
DTEND;TZID=Africa/Nairobi:20251002T203000
DTSTAMP:20260525T004837
CREATED:20250930T124046Z
LAST-MODIFIED:20251223T171811Z
UID:40444-1759431600-1759437000@kesho-kenya.org
SUMMARY:Triple Negative Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nTriple Negative Breast Cancer: Early and Late Stage Management(CPD Accredited) \nDate & Time: \n\n2nd October 2025\n7 PM – 8:30 PM (EAT)\n\nSpeaker: Dr. Joseph AbuodhaConsultant Medical Oncologist\, Department of Haematology and Oncology\, Aga Khan University Hospital\, NairobiTopic: Triple-Negative Breast Cancer: Advancing Care Across Early and Late Stages \nModerator: Dr. Helena MusauConsultant Clinical/Radiation Oncologist and Palliative Care Specialist \nSummary: \nTriple-Negative Breast Cancer: Contemporary Clinical Updates\nPresentation by Dr Joseph Abuodha\n \nDr Joseph Abuodha\, Consultant Medical Oncologist\, delivered a comprehensive clinical update on the biology\, diagnosis and management of triple-negative breast cancer (TNBC)\, highlighting its aggressive nature\, molecular heterogeneity and disproportionate burden in African populations. \nThe presentation outlined the distinctive pathological and molecular characteristics of TNBC\, emphasizing the absence of hormone receptor and HER2 expression\, high-grade histology and frequent genomic instability. Local and global epidemiological data were reviewed\, underscoring the higher prevalence and mortality associated with TNBC in African and African-descended populations. \nManagement strategies across the disease spectrum were discussed\, with chemotherapy reaffirmed as the backbone of treatment in non-metastatic disease. Dr Abuodha highlighted the growing role of neoadjuvant therapy\, particularly for stage II and III disease\, noting that achievement of pathologic complete response (pCR) remains a critical prognostic marker. Evidence supporting the incorporation of platinum agents and immune checkpoint inhibitors in selected patients was reviewed\, alongside adjuvant strategies for residual disease\, including capecitabine and PARP inhibitors in BRCA-mutated cancers. \nIn the metastatic setting\, the importance of repeat biopsy and molecular reassessment was emphasized to guide therapy. Emerging systemic options including immunotherapy\, PARP inhibitors and antibody–drug conjugates were discussed in the context of treatment sequencing and patient selection\, alongside the central role of supportive and palliative care. \nKey takeaway: Triple-negative breast cancer requires a biologically informed\, stage-adapted treatment approach\, with increasing emphasis on neoadjuvant strategies\, molecular testing and integration of novel systemic therapies to improve outcomes in high-risk populations.
URL:https://kesho-kenya.org/event/triple-negative-breast-cancer-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-30-at-9.56.23-AM-e1759236176125.jpeg
END:VEVENT
END:VCALENDAR